DaVita
Q2 2022 Earnings Call
Aug 01, 2022, 5:00 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good evening. My name is Michelle, and I will be your conference facilitator today. At this time, I would like to welcome everyone to the DaVita second quarter 2022 earnings call. [Operator instructions] Thank you.
Mr. Ackerman, you may now begin your conference.
Joel Ackerman -- Chief Financial Officer
Thank you, and welcome, everyone, to our second quarter conference call. We appreciate your continued interest in our company. I am Joel Ackerman, CFO and treasurer, and joining me today is Javier Rodriguez, our CEO. Please note that during this call, we may make forward-looking statements within the meaning of the federal securities laws.
All of these statements are subject to known and unknown risks and uncertainties that could cause the actual results to differ materially from those described in the forward-looking statements. For further details concerning these risks and uncertainties, please refer to our second quarter earnings press release and our SEC filings, including our most recent annual report on Form 10-K and all subsequent quarterly reports on Form 10-Q and other subsequent filings that we make with the SEC. Our forward-looking statements are based on the information currently available to us, and we do not intend and undertake no duty to update these statements except as may be required by law. Additionally, we'd like to remind you that during this call, we will discuss some non-GAAP financial measures.
A reconciliation of these non-GAAP measures to the most comparable GAAP financial measures is included in our earnings press release furnished to the SEC and available on our website. I will now turn the call over to Javier Rodriguez.
Javier Rodriguez -- Chief Executive Officer
Thank you, Joel, and thank you for joining the call. Today, I will cover five topics: health equity, the Supreme Court case, second quarter performance, an update on our integrated kidney care or IKC business, and I will conclude my remarks with our current thinking for 2023. Before we discuss business matters, let me start with a clinical topic that is critical for society, health equity. Given the disproportionate impact kidney disease has on patients of color, health equity is of utmost importance.
Across the key dimensions of access to care, access to information and clinical outcome, DaVita and the kidney care community have achieved unparalleled equity relative to the vast majority of other disease states. We have used the focus of our scale to provide consistent equitable access to care and education. Our leading clinical outcomes and protocols have reduced variability across all patient populations regardless of race or socioeconomic status. Our Black and Hispanic patients are at parity when it comes to dialysis adequacy, phosphorus and calcium lab values as well as hospitalization and mortality.